Summary

The global digital biomarkers market is rapidly evolving as healthcare systems embrace data-centric and technology-driven approaches to patient care. Digital biomarkers, which are objective and quantifiable physiological and behavioral data collected through digital devices such as wearables, sensors, and mobile applications, are transforming how diseases are detected, monitored, and managed. These biomarkers enable continuous health tracking outside traditional clinical settings, supporting more proactive and personalized healthcare delivery. As the demand for remote monitoring and precision medicine continues to rise, digital biomarkers are becoming an integral component of modern healthcare ecosystems.

Market Insights

The digital biomarkers market is expected to reach USD 7.33 billion in 2026 and grow significantly to USD 18.1 billion by 2033, reflecting a strong compound annual growth rate (CAGR) of 13.80% during the forecast period. This robust growth highlights the increasing reliance on digital health technologies across the globe. The expansion of connected health devices, growing investments in digital therapeutics, and the integration of advanced analytics into healthcare systems are contributing to market growth. Additionally, the shift toward patient-centric care and real-time health monitoring is further accelerating the adoption of digital biomarker solutions.

Market Drivers

A range of factors is fueling the growth of the digital biomarkers market. The widespread adoption of wearable devices and smartphones has made it easier to collect continuous and real-time health data. This capability is particularly valuable for managing chronic diseases, enabling early diagnosis and timely interventions.

Technological advancements in artificial intelligence and data analytics are also playing a crucial role in enhancing the accuracy and usability of digital biomarkers. These technologies allow for the processing of large volumes of complex data, enabling better predictive insights and clinical decision-making.

Moreover, the rising prevalence of chronic conditions such as cardiovascular diseases, diabetes, and neurological disorders is increasing the demand for efficient monitoring tools. Healthcare providers are increasingly turning to digital biomarkers as a cost-effective and scalable solution for improving patient outcomes and reducing healthcare costs.

Business Opportunity

The digital biomarkers market offers substantial opportunities for growth and innovation. One of the key opportunities lies in the use of digital biomarkers in clinical trials, where they can provide continuous and objective data, improve patient engagement, and reduce trial durations and costs. Pharmaceutical companies are increasingly leveraging these tools to enhance drug development processes.

Another significant opportunity is in remote patient monitoring, which has gained considerable traction in recent years. Digital biomarkers enable healthcare providers to track patient health in real time, reducing the need for frequent hospital visits and enabling timely interventions.

Collaborations between technology firms, healthcare providers, and research institutions are also creating opportunities for the development of integrated digital health platforms. These platforms combine biomarker data with advanced analytics to deliver comprehensive and personalized healthcare solutions.

Regional Analysis

North America holds the largest share of the digital biomarkers market, supported by advanced healthcare infrastructure, high adoption of digital technologies, and strong investment in research and development. The presence of leading companies and favorable regulatory policies further strengthen the region’s position.

Europe is experiencing steady growth, driven by increasing adoption of digital health solutions and a strong focus on innovation in healthcare delivery. Government initiatives and funding for healthcare digitization are contributing to the market’s expansion in the region.

The Asia Pacific region is anticipated to witness the fastest growth during the forecast period. Factors such as increasing smartphone penetration, rising healthcare awareness, and expanding healthcare infrastructure are driving market growth. Countries in the region are actively investing in digital health technologies to address the growing burden of chronic diseases.

Latin America and the Middle East and Africa are gradually emerging as promising markets, with improving access to healthcare and growing interest in digital solutions supporting their development.

Key Players

The digital biomarkers market is highly competitive, with several key players focusing on innovation, partnerships, and product development to strengthen their market presence. Major companies operating in the market include:

• ActiGraph LLC

• AliveCor Inc.

• Koneksa Health

• Altoida Inc.

• Empatica Inc.

• VivoSense

• IXICO plc

• Adherium Limited

• Neurotrack Technologies Inc.

• Aural Analytics

• Huma

• Sonde Health Inc.

• Biogen Inc.

• Amgen Inc.

• Clario

These organizations are investing in research and development to create advanced solutions that address evolving healthcare needs and expand their global footprint.

Conclusion

The digital biomarkers market is set for significant expansion, driven by the convergence of healthcare and digital technologies. As the demand for personalized, efficient, and remote healthcare solutions continues to grow, digital biomarkers will play a vital role in transforming patient care and clinical research. The market’s strong growth outlook reflects its potential to revolutionize healthcare delivery and improve health outcomes worldwide.

Market Segmentation

By Type

• Wearable

• Mobile Based Applications

• Sensors

• Others

By Clinical Practice

• Diagnostic Digital Biomarkers

• Monitoring Digital Biomarkers

• Predictive And Prognostic Digital Biomarkers

• Other

By Therapeutic Area

• Cardiovascular And Metabolic Disorders (CVMD)

• Respiratory Disorders

• Psychiatric Disorders

• Sleep & Movement Disease

• Neurological Disorders

• Musculoskeletal Disorders

• Others

By End-use

• Healthcare Companies

• Healthcare Providers

• Payers

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Digital Biomarkers Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Digital Biomarkers Market Outlook, 2020-2033
3.1. Global Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
3.1.1. Wearable
3.1.2. Mobile Based Applications
3.1.3. Sensors
3.1.4. Others
3.2. Global Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
3.2.1. Diagnostic Digital Biomarkers
3.2.2. Monitoring Digital Biomarkers
3.2.3. Predictive And Prognostic Digital Biomarkers
3.2.4. Other
3.3. Global Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
3.3.1. Cardiovascular And Metabolic Disorders (CVMD)
3.3.2. Respiratory Disorders
3.3.3. Psychiatric Disorders
3.3.4. Sleep & Movement Disease
3.3.5. Neurological Disorders
3.3.6. Musculoskeletal Disorders
3.3.7. Others
3.4. Global Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
3.4.1. Healthcare Companies
3.4.2. Healthcare Providers
3.4.3. Payers
3.4.4. Others
3.5. Global Digital Biomarkers Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Digital Biomarkers Market Outlook, 2020-2033
4.1. North America Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
4.1.1. Wearable
4.1.2. Mobile Based Applications
4.1.3. Sensors
4.1.4. Others
4.2. North America Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
4.2.1. Diagnostic Digital Biomarkers
4.2.2. Monitoring Digital Biomarkers
4.2.3. Predictive And Prognostic Digital Biomarkers
4.2.4. Other
4.3. North America Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
4.3.1. Cardiovascular And Metabolic Disorders (CVMD)
4.3.2. Respiratory Disorders
4.3.3. Psychiatric Disorders
4.3.4. Sleep & Movement Disease
4.3.5. Neurological Disorders
4.3.6. Musculoskeletal Disorders
4.3.7. Others
4.4. North America Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
4.4.1. Healthcare Companies
4.4.2. Healthcare Providers
4.4.3. Payers
4.4.4. Others
4.5. North America Digital Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.5.1. U.S. Digital Biomarkers Market Outlook, by Type, 2020-2033
4.5.2. U.S. Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
4.5.3. U.S. Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
4.5.4. U.S. Digital Biomarkers Market Outlook, by End-use, 2020-2033
4.5.5. Canada Digital Biomarkers Market Outlook, by Type, 2020-2033
4.5.6. Canada Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
4.5.7. Canada Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
4.5.8. Canada Digital Biomarkers Market Outlook, by End-use, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Digital Biomarkers Market Outlook, 2020-2033
5.1. Europe Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
5.1.1. Wearable
5.1.2. Mobile Based Applications
5.1.3. Sensors
5.1.4. Others
5.2. Europe Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
5.2.1. Diagnostic Digital Biomarkers
5.2.2. Monitoring Digital Biomarkers
5.2.3. Predictive And Prognostic Digital Biomarkers
5.2.4. Other
5.3. Europe Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
5.3.1. Cardiovascular And Metabolic Disorders (CVMD)
5.3.2. Respiratory Disorders
5.3.3. Psychiatric Disorders
5.3.4. Sleep & Movement Disease
5.3.5. Neurological Disorders
5.3.6. Musculoskeletal Disorders
5.3.7. Others
5.4. Europe Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
5.4.1. Healthcare Companies
5.4.2. Healthcare Providers
5.4.3. Payers
5.4.4. Others
5.5. Europe Digital Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.5.1. Germany Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.2. Germany Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.3. Germany Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.4. Germany Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.5. Italy Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.6. Italy Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.7. Italy Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.8. Italy Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.9. France Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.10. France Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.11. France Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.12. France Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.13. U.K. Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.14. U.K. Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.15. U.K. Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.16. U.K. Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.17. Spain Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.18. Spain Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.19. Spain Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.20. Spain Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.21. Russia Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.22. Russia Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.23. Russia Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.24. Russia Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.5.25. Rest of Europe Digital Biomarkers Market Outlook, by Type, 2020-2033
5.5.26. Rest of Europe Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
5.5.27. Rest of Europe Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
5.5.28. Rest of Europe Digital Biomarkers Market Outlook, by End-use, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Digital Biomarkers Market Outlook, 2020-2033
6.1. Asia Pacific Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
6.1.1. Wearable
6.1.2. Mobile Based Applications
6.1.3. Sensors
6.1.4. Others
6.2. Asia Pacific Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
6.2.1. Diagnostic Digital Biomarkers
6.2.2. Monitoring Digital Biomarkers
6.2.3. Predictive And Prognostic Digital Biomarkers
6.2.4. Other
6.3. Asia Pacific Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
6.3.1. Cardiovascular And Metabolic Disorders (CVMD)
6.3.2. Respiratory Disorders
6.3.3. Psychiatric Disorders
6.3.4. Sleep & Movement Disease
6.3.5. Neurological Disorders
6.3.6. Musculoskeletal Disorders
6.3.7. Others
6.4. Asia Pacific Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
6.4.1. Healthcare Companies
6.4.2. Healthcare Providers
6.4.3. Payers
6.4.4. Others
6.5. Asia Pacific Digital Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.5.1. China Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.2. China Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.3. China Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.4. China Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.5.5. Japan Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.6. Japan Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.7. Japan Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.8. Japan Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.5.9. South Korea Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.10. South Korea Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.11. South Korea Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.12. South Korea Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.5.13. India Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.14. India Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.15. India Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.16. India Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.5.17. Southeast Asia Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.18. Southeast Asia Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.19. Southeast Asia Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.20. Southeast Asia Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.5.21. Rest of SAO Digital Biomarkers Market Outlook, by Type, 2020-2033
6.5.22. Rest of SAO Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
6.5.23. Rest of SAO Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
6.5.24. Rest of SAO Digital Biomarkers Market Outlook, by End-use, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Digital Biomarkers Market Outlook, 2020-2033
7.1. Latin America Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
7.1.1. Wearable
7.1.2. Mobile Based Applications
7.1.3. Sensors
7.1.4. Others
7.2. Latin America Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
7.2.1. Diagnostic Digital Biomarkers
7.2.2. Monitoring Digital Biomarkers
7.2.3. Predictive And Prognostic Digital Biomarkers
7.2.4. Other
7.3. Latin America Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
7.3.1. Cardiovascular And Metabolic Disorders (CVMD)
7.3.2. Respiratory Disorders
7.3.3. Psychiatric Disorders
7.3.4. Sleep & Movement Disease
7.3.5. Neurological Disorders
7.3.6. Musculoskeletal Disorders
7.3.7. Others
7.4. Latin America Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
7.4.1. Healthcare Companies
7.4.2. Healthcare Providers
7.4.3. Payers
7.4.4. Others
7.5. Latin America Digital Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.5.1. Brazil Digital Biomarkers Market Outlook, by Type, 2020-2033
7.5.2. Brazil Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
7.5.3. Brazil Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
7.5.4. Brazil Digital Biomarkers Market Outlook, by End-use, 2020-2033
7.5.5. Mexico Digital Biomarkers Market Outlook, by Type, 2020-2033
7.5.6. Mexico Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
7.5.7. Mexico Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
7.5.8. Mexico Digital Biomarkers Market Outlook, by End-use, 2020-2033
7.5.9. Argentina Digital Biomarkers Market Outlook, by Type, 2020-2033
7.5.10. Argentina Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
7.5.11. Argentina Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
7.5.12. Argentina Digital Biomarkers Market Outlook, by End-use, 2020-2033
7.5.13. Rest of LATAM Digital Biomarkers Market Outlook, by Type, 2020-2033
7.5.14. Rest of LATAM Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
7.5.15. Rest of LATAM Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
7.5.16. Rest of LATAM Digital Biomarkers Market Outlook, by End-use, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Digital Biomarkers Market Outlook, 2020-2033
8.1. Middle East & Africa Digital Biomarkers Market Outlook, by Type, Value (US$ Bn), 2020-2033
8.1.1. Wearable
8.1.2. Mobile Based Applications
8.1.3. Sensors
8.1.4. Others
8.2. Middle East & Africa Digital Biomarkers Market Outlook, by Clinical Practice, Value (US$ Bn), 2020-2033
8.2.1. Diagnostic Digital Biomarkers
8.2.2. Monitoring Digital Biomarkers
8.2.3. Predictive And Prognostic Digital Biomarkers
8.2.4. Other
8.3. Middle East & Africa Digital Biomarkers Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
8.3.1. Cardiovascular And Metabolic Disorders (CVMD)
8.3.2. Respiratory Disorders
8.3.3. Psychiatric Disorders
8.3.4. Sleep & Movement Disease
8.3.5. Neurological Disorders
8.3.6. Musculoskeletal Disorders
8.3.7. Others
8.4. Middle East & Africa Digital Biomarkers Market Outlook, by End-use, Value (US$ Bn), 2020-2033
8.4.1. Healthcare Companies
8.4.2. Healthcare Providers
8.4.3. Payers
8.4.4. Others
8.5. Middle East & Africa Digital Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.5.1. GCC Digital Biomarkers Market Outlook, by Type, 2020-2033
8.5.2. GCC Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
8.5.3. GCC Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
8.5.4. GCC Digital Biomarkers Market Outlook, by End-use, 2020-2033
8.5.5. South Africa Digital Biomarkers Market Outlook, by Type, 2020-2033
8.5.6. South Africa Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
8.5.7. South Africa Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
8.5.8. South Africa Digital Biomarkers Market Outlook, by End-use, 2020-2033
8.5.9. Egypt Digital Biomarkers Market Outlook, by Type, 2020-2033
8.5.10. Egypt Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
8.5.11. Egypt Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
8.5.12. Egypt Digital Biomarkers Market Outlook, by End-use, 2020-2033
8.5.13. Nigeria Digital Biomarkers Market Outlook, by Type, 2020-2033
8.5.14. Nigeria Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
8.5.15. Nigeria Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
8.5.16. Nigeria Digital Biomarkers Market Outlook, by End-use, 2020-2033
8.5.17. Rest of Middle East Digital Biomarkers Market Outlook, by Type, 2020-2033
8.5.18. Rest of Middle East Digital Biomarkers Market Outlook, by Clinical Practice, 2020-2033
8.5.19. Rest of Middle East Digital Biomarkers Market Outlook, by Therapeutic Area, 2020-2033
8.5.20. Rest of Middle East Digital Biomarkers Market Outlook, by End-use, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. ActiGraph LLC
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. AliveCor Inc.
9.4.3. Koneksa Health
9.4.4. Altoida Inc.
9.4.5. Empatica Inc.
9.4.6. VivoSense
9.4.7. IXICO plc
9.4.8. Adherium Limited
9.4.9. Neurotrack Technologies Inc.
9.4.10. Aural Analytics
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations